3-Year clinical outcomes in the randomized SORT OUT III superiority trial comparing zotarolimus- and sirolimus-eluting coronary stents

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

  • Michael Maeng
  • Hans-Henrik Tilsted
  • Lisette Okkels Jensen
  • Anne Kjer Kaltoft
  • Henning Kelbæk
  • Ulrik Abildgaard
  • Anton B Villadsen
  • Lars Romer Krusell
  • Jan Ravkilde
  • Knud Nørregaard Hansen
  • Evald Høj Christiansen
  • Jens Aarøe
  • Jan Skov Jensen
  • Steen Dalby Kristensen
  • Hans Erik Bøtker
  • Morten Madsen
  • Per Thayssen
  • Henrik Toft Sørensen
  • Leif Thuesen
  • Jens Flensted Lassen
This study sought to examine the 3-year clinical outcomes in patients treated with the Endeavor (Medtronic, Santa Rosa, California) zotarolimus-eluting stent (ZES) or the Cypher (Cordis, Johnson & Johnson, Warren, New Jersey) sirolimus-eluting stent (SES) in routine clinical practice.
OriginalsprogEngelsk
TidsskriftCirculation. Cardiovascular Interventions
Vol/bind5
Udgave nummer8
Sider (fra-til)812-8
Antal sider7
ISSN1941-7640
DOI
StatusUdgivet - 2012

ID: 48477036